MCID: HMP004
MIFTS: 62

Hemophilia B malady

Categories: Genetic diseases, Rare diseases, Blood diseases

Aliases & Classifications for Hemophilia B

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Hemophilia B:

Name: Hemophilia B 52 11 23 48 24 54 70 27 12 50 39 13 68
Factor Ix Deficiency 11 23 48 24 54 70
Christmas Disease 23 48 24 54 70
Plasma Thromboplastin Component Deficiency 70
Deficiency, Functional Factor Ix 11
Recessive X-Linked Hemophilia B 70
 
Congenital Factor Ix Deficiency 11
Congenital Factor Ix Disorder 11
F9 Deficiency 70
Hem B 48
Hemb 70

Characteristics:

Orphanet epidemiological data:

54
hemophilia b:
Inheritance: X-linked recessive; Prevalence: 1-9/100000 (Europe); Age of onset: Infancy,Neonatal

HPO:

64
hemophilia b:
Inheritance: x-linked recessive inheritance

GeneReviews:

23
Penetrance: all males with an f9 pathogenic variant are affected and will have hemophilia b of approximately the same severity as all other affected males in the family; however, other genetic and environmental effects may modify the clinical severity to some extent. ...


Classifications:



External Ids:

OMIM52 306900
Disease Ontology11 DOID:12259
ICD1030 D67
ICD9CM32 286.1
MeSH39 D002836
NCIt45 C26721
Orphanet54 ORPHA98879
MESH via Orphanet40 D002836
ICD10 via Orphanet31 D67
UMLS via Orphanet69 C0008533

Summaries for Hemophilia B

About this section
OMIM:52 Hemophilia B due to factor IX deficiency is phenotypically indistinguishable from hemophilia A (306700), which results... (306900) more...

MalaCards based summary: Hemophilia B, also known as factor ix deficiency, is related to artery disease and myocardial infarction, and has symptoms including degenerative joint disease, abnormal bleeding and persistent bleeding after trauma. An important gene associated with Hemophilia B is F9 (Coagulation Factor IX), and among its related pathways are Gamma carboxylation, hypusine formation and arylsulfatase activation and Warfarin Pathway, Pharmacodynamics. The drugs recombinant fviia and coagulation factor ix (recombinant human) have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related mouse phenotypes are immune system and cardiovascular system.

Disease Ontology:11 An inherited blood coagulation disease that has material basis in Factor IX deficiency, which makes coagulation much more prolonged. The disease is inherited as an X-linked recessive trait.

NIH Rare Diseases:48 Hemophilia B is a bleeding disorder that slows the blood clotting process. People with this disorder experience prolonged bleeding or oozing following an injury or surgery. In severe cases of hemophilia, heavy bleeding occurs after minor injury or even in the absence of injury. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms may not become apparent until abnormal bleeding occurs following surgery or a serious injury. People with an unusual form of hemophilia B, known as hemophilia B Leyden, experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty. Hemophilia B is inherited in an X-linked recessive pattern and is caused by mutations in the F9 gene. Last updated: 2/8/2016

UniProtKB/Swiss-Prot:70 Hemophilia B: An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma.

GeneReviews for NBK1495

Related Diseases for Hemophilia B

About this section

Diseases in the Hemophilia family:

hemophilia b Hemophilia a
Acquired Hemophilia Acquired Hemophilia a
Severe Hemophilia a Severe Hemophilia B

Diseases related to Hemophilia B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 161)
idRelated DiseaseScoreTop Affiliating Genes
1artery disease30.1F2, F3
2myocardial infarction27.1F10, F11, F2, F3, F7, F8
3severe hemophilia b12.1
4mild hemophilia b12.0
5moderately severe hemophilia b12.0
6symptomatic form of hemophilia b in female carriers11.9
7hemophilia10.9
8familial glomangioma10.5F2, F3
9high anorectal malformation10.5F8, F9
10cerebral angioma10.5F2, F3
11classic congenital lipoid adrenal hyperplasia due to star deficency10.5F2, F3
12dislocation of ear ossicle10.5F2, F3
13epididymo-orchitis10.5F2, F3
14chorea gravidarum10.5F2, F3
15peroneal neuropathy10.5F2, F3
16splenic infarction10.4F2, F3
17cercarial dermatitis10.4F2, F3
18tympanosclerosis10.4F2, F8
19glossopharyngeal nerve disease10.4F10, F3
20west nile fever10.4F2, F8
21idiopathic neutropenia10.4F3, F8
22secondary central precocious puberty10.4F10, F8
23ovarian cystic teratoma10.4F2, F3
24typhoid fever10.3F2, F7
25van maldergem syndrome 210.3F2, F8
26esophagus leiomyosarcoma10.3F7, F9
27pneumocystosis10.3F11, F3
28pancreatic solid pseudopapillary carcinoma10.3F2, F7
29cavernous sinus thrombosis10.3F3, SERPINC1
30irak4 deficiency10.3F10, F2
31subcortical arteriosclerotic encephalopathy10.3F2, SERPINC1
32congenital nystagmus10.3F2, F3, F9
33thyroid hyalinizing trabecular adenoma10.2F2, SERPINC1
34milk allergy10.2F2, SERPINC1
35xfe progeroid syndrome10.2F9, SERPINC1
36collagenous colitis10.2F2, SERPINC1
37chronic diarrhea due to guanylate cyclase 2c overactivity10.2F3, SERPINC1
38hypertensive heart disease10.2F2, SERPINC1
39spleen cancer10.2F2, SERPINC1
40hepatic coma10.2F2, F3
41posterolateral myocardial infarction10.2F2, SERPINC1
42venezuelan hemorrhagic fever10.2F8, SERPINC1
43hemophilia a10.2
44may-hegglin anomaly10.2F2, SERPINC1
45left-right axis malformations10.2F2, SERPINC1
46histoplasmosis10.2F2, SERPINC1
47diabetic autonomic neuropathy10.2F2, F8, F9
48apocrine adenoma10.2F2, F3
49coronary restenosis10.2F3, SERPINC1
50von willibrand disease, type 310.2F2, F3, F8

Graphical network of the top 20 diseases related to Hemophilia B:



Diseases related to hemophilia b

Symptoms & Phenotypes for Hemophilia B

About this section

Symptoms by clinical synopsis from OMIM:

306900

Clinical features from OMIM:

306900

Human phenotypes related to Hemophilia B:

 64 (show all 8)
id Description HPO Frequency HPO Source Accession
1 degenerative joint disease64 HP:0001379
2 abnormal bleeding64 HP:0001892
3 persistent bleeding after trauma64 HP:0001934
4 gastrointestinal hemorrhage64 HP:0002239
5 prolonged partial thromboplastin time64 HP:0003645
6 joint hemorrhage64 HP:0005261
7 prolonged whole-blood clotting time64 HP:0005542
8 reduced factor ix activity64 HP:0011858

MGI Mouse Phenotypes related to Hemophilia B according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053877.8EGF, F11, F2, F3, F8, F9
2MP:00053857.8F10, F11, F2, F3, F7, F9
3MP:00053767.4F10, F11, F2, F3, F7, F8
4MP:00107686.6F10, F11, F2, F3, F7, F8

Drugs & Therapeutics for Hemophilia B

About this section

Drugs for Hemophilia B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 139)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
IndinavirapprovedPhase 4, Phase 2110150378-17-95362440
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC-20034
AC1L1U7I
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
 
C36H47N5O4
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
indinavir
2
Stavudineapproved, investigationalPhase 4, Phase 21723056-17-518283
Synonyms:
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
3056-17-5
AC-5263
AC1L2BQ9
AC1Q6BSH
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY-27857
BMY27857
BRN 0618327
Bristol-Myers Brand of Stavudine
Bristol-Myers Squibb Brand of Stavudine
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
D4T & GM-CSF
D4TMBY-27857-3
DB00649
Dideoxydidehydrothymidine
EU-0100336
Estavudina
Estavudina [INN-Spanish]
FT-0082665
 
HMS2051O20
HSDB 7338
LS-1160
Lopac0_000336
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
SMR000058350
SMR000673569
STK801888
STV
Sanilvudine
Sanilvudine (JAN)
Stavudin
Stavudine
Stavudine (USAN/INN)
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine [Usan:Ban:Inn]
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
ZINC00137884
Zent
Zerit
Zerit (TN)
Zerit XR
Zerit Xr
Zerit(TM)
Zerut XR
d4T
ddeThd
ddeTyd
sanilvudine
stavudine
3
Lamivudineapproved, investigationalPhase 4, Phase 2613134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
 
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine
4
RopivacaineapprovedPhase 474184057-95-471273, 175805
Synonyms:
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
(S)-(−)-1-propyl-2',6'-pipecoloxylidide
(S)-ropivacaine
84057-95-4
98717-15-8
AC1L41QM
AC1L41QN
BIDD:GT0203
C07532
C17H26N2O.HCl
CHEBI:8890
CHEMBL1077896
CID175804
CID175805
CPD000469137
D08490
I14-176
L-N-n-propylpipecolic acid-2,6-xylidide
LS-113954
 
MLS001401363
MolPort-003-983-292
NCGC00164597-01
Naropin
Naropin (TN)
ROPIVACAINE HCl
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
SAM001246524
SMR000469137
ST51051452
ropivacaine monohydrochloride,
ropivacaine monohydrochloride, (S)-isomer
5
Triamcinoloneapproved, vet_approvedPhase 4482124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
6
ZidovudineapprovedPhase 4, Phase 3, Phase 249430516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
 
CPD000058351
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
7
Hyaluronic acidapproved, vet_approvedPhase 44399004-61-953477741, 24759
Synonyms:
Hyaluronan
Hyaluronate
Hyaluronic acid
Hylartil
Hyruan Plus
Luronit
 
Macronan
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sofast
Synvisc
8
HistamineapprovedPhase 4103475614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
9
ZalcitabineapprovedPhase 4477481-89-224066
Synonyms:
.beta.-D-2',3'-Dideoxycytidine
.beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
.beta.-D-DDC
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine
16803P
2',3'-DIDEOXYCYTIDINE
2',3'-Dideoxycytidine
2',3'-Dideoxycytidine & Interferon.alpha.
2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate)
2',3'-Dideoxycytidine & sCD4(soluble recombinant protein)
2,3-dideoxycytidine
3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine
36775_FLUKA
4-amino-1-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
5-25-14-00313 (Beilstein Handbook Reference)
7481-89-2
AC-824
AC1L2N6R
BPBio1_001378
BRN 0654956
BSPBio_001253
C07207
C9H13N3O3
CCRIS 692
CHEBI:10101
CHEMBL853
CID24066
CPD000058253
Cytidine, 2',3'-dideoxy- & Colony-stimulating factor
Cytidine, 2',3'-dideoxy- & Interferon.alpha.
D 5782
D00412
D3581
D5782_SIGMA
DB00943
DDC
DDC (DDC)
DDCYD
DS-4152 & ddC
Dideoxycytidine
EU-0100360
HIVID
HMS1548B19
HMS1571O15
HMS2051H18
HMS2090C12
HSDB 7156
Hivid (TN)
Hivid(TM)
 
Hivid, Dideoxycytidine, NSC 606170, Zalcitabine
Interferon AD + ddC
KS-1130
LS-1645
Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine
Lopac0_000360
MLS000069636
MLS000759540
MLS001055363
MLS001424210
MolPort-002-885-873
NCGC00090705-01
NCGC00090705-02
NCGC00090705-03
NCGC00090705-05
NCGC00090705-06
NCGC00090705-07
NCGC00090705-10
NCGC00179242-01
NSC 606170
NSC-606170
NSC606170
PC-SOD & ddC
Prestwick0_001037
Prestwick1_001037
Prestwick2_001037
Prestwick3_001037
Ro 24-2027/000
Ro-24-2027/000
S1719_Selleck
SAM001246779
SMR000058253
SPBio_003104
SRI-7707
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine
TimTec1_004969
UNII-6L3XT8CB3I
UPCMLD-DP115
UPCMLD-DP115:001
ZINC00039906
Zalcitabine (JAN/USP/INN)
Zalcitabine [USAN:INN:BAN]
Zalcitibine
bmse000712
ddC
ddC & GM-CSF
ddC & IFN.alpha.
ddC & Interferon.alpha.
ddC & NP (from PHCA or HSA)
ddC & sCD4
ddC (Antiviral)
ddCyd
zalcitabine
10
Histamine PhosphateapprovedPhase 4103351-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
11
MentholapprovedPhase 423532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
12
DidanosineapprovedPhase 4, Phase 215069655-05-650599
Synonyms:
149409-57-4
2',3'-Dideoxyinosine
2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor
2',3'-Dideoxyinosine & Interferon-.alpha.
2',3'-Dideoxyinosine & sCD4(soluble recombinant protein)
2',3'-Dideoxyinosine (AIDS Initiative)
2',3'-Dideoxyinosine (ddI)
2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine
2'3'-DIDEOXYINOSINE
2,3-Dideoxyinosine
2,3-dideoxyinosine
2DI
3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine
69655-05-6
9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
AC-12026
AC1L19ET
AC1L3OPK
BMY 40900
BMY-40900
BRN 3619529
Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride
Bio-0685
C06953
C083832
CCRIS 805
CHEBI:490877
CHEMBL1460
CID119381
CID50599
CPD000058576
D00296
D2I
D3066
DB00900
DB02392
DDI
DDI and rIFN.alpha.2
DIDEOXYINOSINE
DRG-0016
DS-4152 & ddI
DdIno
Didanosina
 
Didanosina [INN-Spanish]
Didanosine
Didanosine (JAN/USAN/INN)
Didanosine and Interferon-.alpha.-2
Didanosinum
Didanosinum [INN-Latin]
Dideoxyinosine
Dideoxyinosine (DDI)
FT-0082664
HMS2051J11
HMS2089N20
HSDB 6548
Hypoxanthine ddN
Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2
Intron A & Videx
KS-1049
LOA & ddI
Listera ovata agglutinin & 2',3'-Dideoxyinosine
MLS000759469
MLS001055350
MLS001424118
MLS002154216
MolPort-002-507-371
MolPort-002-885-819
N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride
N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride
NCGC00090691-01
NCGC00159514-02
NCGC00159514-03
NCGC00164280-01
NE 100
NE-100
NSC 612049
NSC-612049
NSC612049
PC-SOD+ddI
S1702_Selleck
SAM001246673
SMR000058576
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine
UNII-K3GDH6OH08
Videx
Videx (TN)
Videx EC
Videx EC(TM)(slow-release capsules)
Videx(TM)
ZINC13597823
ddI & GM-CSF
ddI & IFN-.alpha.
ddI & sCD4(rsCD4)
ddI + d4T combination
ddIno
didanosine
13
Heparinapproved, investigationalPhase 48129005-49-6772, 46507594
Synonyms:
101921-26-0
102-94-3
102785-31-9
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
AR-1E4539
Allocinnamic acid
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
CID772
CID8784
CY 216
Calciparine
Certoparin
Clexane
Clivarin
Clivarine
Cy 222
D006495
D017984
DB00407
DB01225
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT-966
EMT-967
EMT966
EMT967
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
FR 860
Fluxum
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
HSDB 3094
Hed-heparin
Hep Flush Kit in plastic container
Hep-Lock
Hep-Lock U/P
Hep-lock
Heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin Sodium
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
 
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Inno-Hep
Innohep
Isocinnamic acid
KB 101
Kabi 2165
LHN 1
LMWH
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Lovenox
Lovenox HP
Low Molecular Weight Heparin
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
NSC174025
Nadroparin
Nadroparine
Novoheparin
OP 386
OP 622
Octaparin
PK 10,169
PK-10,169
PK-10169
PK10,169
PK10169
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Unfractionated heparin
Vetren
Vitrum AB
WY 90493RD
alpha-Heparin
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
enoxaparin
heparin
14
ApixabanapprovedPhase 4134503612-47-310182969
Synonyms:
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
2p16
503612-47-3
AKOS005146204
Apixaban
Apixaban (JAN/USAN/INN)
BMS 562247-01
BMS-562247
BMS-562247-01
BMS-562247-01, Apixaban
 
CHEBI:49620
CHEMBL231779
CID10182969
D03213
DB07828
GG2
S1593_Selleck
UNII-3Z9Y7UWC1J
apixabanum
apixabán
ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide
15
DalteparinapprovedPhase 43039041-08-1
Synonyms:
Daltepariininatrium
Dalteparin Sodyum
Dalteparin sodium
Dalteparin sodná sůl
Dalteparin-nátrium
Dalteparina sódica
 
Dalteparinnatrium
Dalteparino natrio druska
Dalteparinum Natricum
Dalteparyna sodowa
Daltéparine sodique
Heparin Fragment KABI 2165
Tedelparin
16
Phytonadioneapproved, NutraceuticalPhase 4, Phase 323084-80-04812, 5284607
Synonyms:
.alpha.-Phylloquinone
1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-)
10485-69-5
11104-38-4
15973-57-6
2', 3'-trans-Vitamin K1
2',3'-trans-Vitamin K1
2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione
2-METHYL-3-PHYTYL-14-NAPHTHOQUINONE
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened- ione
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone
2-Methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
2-Methyl-3-phythyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthochinon [German]
2-Methyl-3-phytyl-1,4-naphthoquinone
2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione
2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
27696-10-2
3-Phytylmenadione
50926-17-5
84-80-0
AC1NQX34
AC1Q6B3J
AR-1E3503
Antihemorrhagic vitamin
Aqua mephyton
Aqua-Mephytin
Aquamephyton
C02059
C31H46O2
CID5280483
Combinal K1
D00148
DB01022
EINECS 201-564-2
EINECS 234-330-3
EINECS 279-833-9
Fitomenadiona
Fitomenadiona [INN-Spanish]
Fitomenadione
Fitomenadione [DCIT]
HSDB 3162
K-Ject
Kativ N
Kephton
 
Kinadion
Konakion
LS-94617
LT00452032
MLS001332659
MLS001332660
Mephyton
Mephyton (TN)
MolPort-001-785-978
Mono-Kay
Monodion
NCGC00159423-02
NSC 270681
NSC270681
P0642
Phyllochinon
Phyllochinon [German]
Phyllochinonum
Phylloquinone
Phylloquinone (8CI)
Phythyl-menadion
Phythyl-menadion (GERMAN)
Phytomenadione
Phytomenadione (INN)
Phytomenadionum
Phytomenadionum [INN-Latin]
Phytonadione
Phytonadione (JP15/USP)
Phytonadione [USAN:JAN]
Phytonadionum
Phytylmenadione
SMR000059144
ST075162
Synthex P
UNII-A034SE7857
VITAMIN K
VITAMIN K1
Vitamin K
Vitamin K 1
Vitamin K1
Vitamin K1 (TN)
Vitamin K1 (VAN)
Vitamin K1 (generic)
Vitamin K1(20)
alpha-Phylloquinone
phyllohydroquinone
phytonadione
trans-Phylloquinone
α-phylloquinone
17
Menadioneapproved, nutraceuticalPhase 4, Phase 323058-27-54055
Synonyms:
03AAE1E9-B215-45AF-976C-91E61894A467
1,4-Naphthalenedione, 2-methyl-, radical ion(1-)
2-Methyl-1,4-Naphthalenedione
2-Methyl-1,4-naftochinon
2-Methyl-1,4-naftochinon [Czech]
2-Methyl-1,4-naphthalendione
2-Methyl-1,4-naphthalenedione
2-Methyl-1,4-naphthochinon
2-Methyl-1,4-naphthochinon [German]
2-Methyl-1,4-naphthodione
2-Methyl-1,4-naphthoquinone
2-Methylnaphthoquinone
2-methyl-1,4-naphthoquinone, 5
2-methylnaphthalene-1,4-dione
3-Methyl-1,4-naphthoquinone
34524-96-4
47775_SUPELCO
58-27-5
72060-21-0
AC1L1HBA
AC1Q2HB3
AI3-14700
AKOS004910447
ARONIS24154
Aquakay
Aquinone
BB_NC-2319
BIDD:ER0556
BPBio1_000592
BSPBio_000538
Bio1_000471
Bio1_000960
Bio1_001449
C05377
C11H8O2
CAS-58-27-5
CCRIS 6672
CHEBI:28869
CHEMBL590
CID4055
CPD-3766
D02335
DB00170
DivK1c_000080
DivK1c_006287
EINECS 200-372-6
HMS1569K20
HMS1921P06
HMS2092F12
HMS500D22
HSDB 3354
Hemodal
I14-2821
IDI1_000080
InChI=1/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H
Juva-K
K-Thrombyl
K-Vitan
KBio1_000080
KBio1_001231
KBio2_001708
KBio2_002527
KBio2_004276
KBio2_005095
KBio2_006844
KBio2_007663
KBio3_003005
KBioGR_000984
KBioGR_002527
KBioSS_001708
KBioSS_002535
Kaergona
Kanone
Kappaxan
Kappaxan (VAN)
Kappaxin
Kappaxin (TN)
Karcon
Kareon
Kativ-G
Kayklot
Kaykot
 
Kaynone
Kayquinone
Kipca
Kipca, oil soluble
Kipca-Oil Soluble
Klottone
Koaxin
Kolklot
LS-95653
LS-95654
M0373
M5625_SIGMA
M9429_SIGMA
MLS000069420
MLS001148443
MNQ
Memodol
Menadion
Menadione
Menadione (K3)
Menadione (USP)
Menadione [USAN:BAN]
Menadione semiquinone
Menadionum
Menaphthene
Menaphthon
Menaphthone
Menaphtone
Menaquinone
Menaquinone 0
Menaquinone O
Methyl-1,4-naphthalenedione
Methyl-1,4-naphthoquinone
Methylnaphthoquinone
Mitenon
Mitenone
MolPort-001-766-699
NCGC00016258-01
NCGC00094978-01
NCGC00094978-02
NCI60_003945
NCIMech_000105
NINDS_000080
NSC 4170
NSC4170
Panosine
Prestwick0_000459
Prestwick1_000459
Prestwick2_000459
Prestwick3_000459
Prestwick_313
Prokayvit
QTL1_000056
S1949_Selleck
SMR000059102
SMR000653532
SPBio_001267
SPBio_002477
SPECTRUM1502254
SpecPlus_000191
Spectrum2_001194
Spectrum4_000722
Spectrum5_001764
Spectrum_001228
Synkay
Thyloquinone
UNII-723JX6CXY5
Usaf ek-5185
VK3
Vicasol
Vitamin K 3
Vitamin K0
Vitamin K2
Vitamin K2(0)
Vitamin K3
Vitamin K3 : 2-Methyl-1,4-naphthoquinone
Vitamin K3: 1,4-Dihydro-1,4-dioxo-2-methylnaphthalene
Vitamin-?K3
WLN: L66 BV EVJ C1
ZINC00001677
cMAP_000077
menadione
nchembio.109-comp5
18
Vitamin Aapproved, nutraceutical, vet_approvedPhase 446811103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
19Anti-Retroviral AgentsPhase 4, Phase 3, Phase 2, Phase 13232
20Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 19732
21Factor VIIIPhase 4, Phase 3, Phase 2, Phase 1304
22Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
23Anti-HIV AgentsPhase 4, Phase 3, Phase 2, Phase 13100
24Protein CPhase 4, Phase 3115
25AntibodiesPhase 4, Phase 3, Phase 26045
26Factor Xa InhibitorsPhase 4, Phase 1391
27Pharmaceutical SolutionsPhase 4, Phase 3, Phase 17793
28VitaminsPhase 4, Phase 35095
29Serine Proteinase InhibitorsPhase 4, Phase 3, Phase 1850
30AntithrombinsPhase 4, Phase 3, Phase 1672
31Antithrombin IIIPhase 4, Phase 3, Phase 1665
32ImmunoglobulinsPhase 4, Phase 3, Phase 26045
33Triamcinolone diacetatePhase 4482
34Triamcinolone hexacetonidePhase 4482
35ViscosupplementsPhase 4364
36Adjuvants, ImmunologicPhase 42484
37triamcinolone acetonidePhase 4482
38Reverse Transcriptase InhibitorsPhase 4, Phase 3, Phase 21880
39HylanPhase 445
40Protective AgentsPhase 47190
41AnticoagulantsPhase 4, Phase 3, Phase 2, Phase 12516
42CoagulantsPhase 4, Phase 3, Phase 2, Phase 11428
43Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 24855
44
protease inhibitorsPhase 4, Phase 3, Phase 2, Phase 15320
Synonyms:
 
protease inhibitors
45AntimetabolitesPhase 4, Phase 3, Phase 211774
46HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 15319
47ThrombinPhase 4, Phase 3, Phase 1288
48HemostaticsPhase 4, Phase 3, Phase 2, Phase 11359
49Retinol palmitatePhase 4468
50Heparin, Low-Molecular-WeightPhase 4320

Interventional clinical trials:

(show top 50)    (show all 233)
idNameStatusNCT IDPhase
1Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia BCompletedNCT00581126Phase 4
2Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in ChinaCompletedNCT02336178Phase 4
3Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)CompletedNCT00139828Phase 4
4Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual UseCompletedNCT00167973Phase 4
5Study Evaluating Allergic Reactions To Benefix In Hemophilia B PatientsCompletedNCT00244114Phase 4
6Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IXCompletedNCT00749476Phase 4
7Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia BCompletedNCT00195221Phase 4
8IMMUNINE Pre-Treatment StudyCompletedNCT01128881Phase 4
9Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle ArthropathyCompletedNCT00638001Phase 4
10Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedNCT01561391Phase 4
11Viscosupplementation in Patients With Hemophilic ArthropathyCompletedNCT01748201Phase 4
12Trial of NovoSeven® in Haemophilia - Joint BleedsCompletedNCT00108797Phase 4
13High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With InhibitorsCompletedNCT00571584Phase 4
14Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant ReversalCompletedNCT01159210Phase 4
15Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With HemophiliaCompletedNCT00002386Phase 4
16Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A PatientsCompletedNCT00914459Phase 4
17Study Evaluating ReFacto® in Hemophilia A Undergoing Major SurgeryCompletedNCT00092976Phase 4
18Study Comparing Blood Levels of ReFacto and Advante in Hemophilia ACompletedNCT00168051Phase 4
19Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care SettingCompletedNCT00950170Phase 4
20PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Phase 4
21Survey of Inhibitors in Plasma-Product Exposed ToddlersCompletedNCT01064284Phase 4
22Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical PatientsRecruitingNCT02777424Phase 4
23Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia ARecruitingNCT00323856Phase 4
24Apixaban for the Acute Treatment of Venous Thromboembolism in ChildrenRecruitingNCT02464969Phase 4
25Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGOActive, not recruitingNCT01959919Phase 4
26Study Evaluating The Safety Of Xyntha In Usual Care SettingsTerminatedNCT00765726Phase 4
27Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care SettingsTerminatedNCT00884390Phase 4
28Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B PatientsCompletedNCT01174446Phase 3
29Study Evaluating rFIX; BeneFIX in Severe Hemophilia BCompletedNCT00037557Phase 3
30Study Evaluating On-Demand Treatment With BeneFIX In Chinese SubjectsCompletedNCT00866606Phase 3
31Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia BCompletedNCT01335061Phase 3
32A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia BCompletedNCT02263456Phase 3
33Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia BCompletedNCT00364182Phase 3
34An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing SurgeryCompletedNCT02250573Phase 3
35A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 YearsCompletedNCT02263469Phase 3
36Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BCompletedNCT01440946Phase 3
37Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia BCompletedNCT01027364Phase 3
38BAX 326 Surgery Study in Hemophilia B PatientsCompletedNCT01507896Phase 3
39A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia BCompletedNCT01662531Phase 3
40A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT01496274Phase 2, Phase 3
41A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.CompletedNCT02250560Phase 3
42An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B PatientsCompletedNCT02231944Phase 3
43Study Evaluating rFIX; BeneFIX® in Hemophilia BCompletedNCT00093171Phase 3
44Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B PatientsCompletedNCT01333111Phase 3
45Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia BCompletedNCT01386528Phase 3
46Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773CompletedNCT01395810Phase 3
47Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia BCompletedNCT00093210Phase 3
48BAX 326 Pediatric StudyCompletedNCT01488994Phase 2, Phase 3
49Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand RegimenCompletedNCT01757405Phase 3
50Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer InhibitorCompletedNCT00851721Phase 3

Search NIH Clinical Center for Hemophilia B

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: hemophilia b

Genetic Tests for Hemophilia B

About this section

Genetic tests related to Hemophilia B:

id Genetic test Affiliating Genes
1 Hemophilia B(m)27
2 Hemophilia B24 F9

Anatomical Context for Hemophilia B

About this section

MalaCards organs/tissues related to Hemophilia B:

36
Liver, Brain, Testes, Bone, Skin, Skeletal muscle, Whole blood

Publications for Hemophilia B

About this section

Articles related to Hemophilia B:

(show top 50)    (show all 551)
idTitleAuthorsYear
1
Usual and unusual mutations in a cohort of Belgian patients with hemophilia B. (27865967)
2017
2
Identification of a novel mutation in HPS6 in a patient with hemophilia B and oculocutaneous albinism. (27641950)
2016
3
Mutational Analysis of Hemophilia B in Russia: Molecular-Genetic Study]. (27529981)
2016
4
A milder clinical course for severe hemophilia B: a true or biased effect? (27252514)
2016
5
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. (26969334)
2016
6
Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX. (27052253)
2016
7
Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. (27174727)
2016
8
A genetic analysis of 23 Chinese patients with hemophilia B. (27109384)
2016
9
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. (27942241)
2016
10
Difficulties in the treatment of an Infant with Hemophilia B. (27489472)
2016
11
New developments in the management of moderate-to-severe hemophilia B. (27099538)
2016
12
The higher prevalence of missense mutations in hemophilia B compared to hemophilia A could be important in determining a milder clinical phenotype in patients with severe hemophilia B. (27694504)
2016
13
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice. (26840952)
2016
14
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. (26755710)
2016
15
Why should hemophilia B be milder than hemophilia A? (27132281)
2016
16
Biodegradable hydrophilic carriers for the oral delivery of hematological factor IX for hemophilia B treatment. (27863665)
2016
17
Laparoscopic nephrectomy in a hemophilia B patient. (27729993)
2016
18
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. (27356951)
2016
19
Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay. (27501440)
2016
20
A new era for hemophilia B treatment. (27056991)
2016
21
Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). (27288064)
2016
22
First Diagnosis of Hemophilia B in a Nonagenarian. (26782891)
2016
23
Taylor JA, Kruse-Jarres R. A new era for hemophilia B treatment. Blood. 2016;127(14):1734-1736. (27737849)
2016
24
Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. (27513989)
2016
25
A Factor VIIa Variant with Enhanced Tissue Factor Independent Activity Speeds Wound Healing in a Mouse Hemophilia B Model. (26952654)
2016
26
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. (27106122)
2016
27
SVA retrotransposition in exon 6 of the coagulation factor IX gene causing severe hemophilia B. (25739383)
2015
28
Gene therapy in an era of emerging treatment options for hemophilia B. (26149016)
2015
29
Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. (25675273)
2015
30
Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention. (25370152)
2015
31
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. (25419787)
2015
32
Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk. (26387706)
2015
33
Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients. (26023895)
2015
34
Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. (26494839)
2015
35
EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France. (25652955)
2015
36
Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor. (25811452)
2015
37
Hemophilia B acquired through liver transplantation. (26515506)
2015
38
Hemophilia B: Molecular Pathogenesis and Mutation Analysis. (25851415)
2015
39
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. (25568350)
2015
40
A natural choice for hemophilia B. (25745178)
2015
41
New and improved AAVenues: current status of hemophilia B gene therapy. (26524468)
2015
42
Hepatocyte-like cells derived from mouse induced pluripotent stem cells produce functional coagulation factor IX in a hemophilia B mouse model. (26395869)
2015
43
Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B. (25663062)
2015
44
Liver-directed lentiviral gene therapy in a dog model of hemophilia B. (25739762)
2015
45
Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. (26302233)
2015
46
Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B. (25539053)
2015
47
Moving forward toward a cure for hemophilia B. (25943496)
2015
48
Spinal epidural hematoma in a patient with hemophilia B presenting as acute abdomen. (25332535)
2014
49
Hemophilia B Leyden and once mysterious cis-regulatory mutations. (24138812)
2014
50
Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs. (25548971)
2014

Variations for Hemophilia B

About this section

UniProtKB/Swiss-Prot genetic disease variations for Hemophilia B:

70 (show all 138)
id Symbol AA change Variation ID SNP ID
1F9p.Ile17AsnVAR_006521
2F9p.Cys28ArgVAR_006522rs387906481
3F9p.Val30IleVAR_006523
4F9p.Arg43GlnVAR_006524
5F9p.Arg43LeuVAR_006525
6F9p.Arg43TrpVAR_006526
7F9p.Lys45AsnVAR_006527
8F9p.Arg46SerVAR_006528
9F9p.Arg46ThrVAR_006529
10F9p.Asn48IleVAR_006530
11F9p.Ser49ProVAR_006531
12F9p.Glu53AlaVAR_006532
13F9p.Glu54GlyVAR_006533
14F9p.Phe55CysVAR_006534
15F9p.Gly58AlaVAR_006535
16F9p.Gly58ArgVAR_006536
17F9p.Glu66ValVAR_006538
18F9p.Glu67LysVAR_006539
19F9p.Phe71SerVAR_006540
20F9p.Glu73LysVAR_006541rs137852225
21F9p.Glu73ValVAR_006542rs137852226
22F9p.Tyr91CysVAR_006543
23F9p.Asp93GlyVAR_006544rs137852230
24F9p.Gln96ProVAR_006545rs137852231
25F9p.Cys97SerVAR_006546
26F9p.Pro101ArgVAR_006547
27F9p.Cys102ArgVAR_006548
28F9p.Gly106SerVAR_006549rs137852233
29F9p.Cys108SerVAR_006550
30F9p.Asp110AsnVAR_006551rs137852274
31F9p.Ile112SerVAR_006552
32F9p.Asn113LysVAR_006553
33F9p.Tyr115CysVAR_006554
34F9p.Cys119PheVAR_006555
35F9p.Cys119ArgVAR_006556
36F9p.Gly125GluVAR_006557
37F9p.Gly125ValVAR_006558
38F9p.Ile136ThrVAR_006560
39F9p.Gly139AspVAR_006561
40F9p.Gly139SerVAR_006562
41F9p.Cys155PheVAR_006563
42F9p.Gly160GluVAR_006564
43F9p.Gln167HisVAR_006565
44F9p.Cys178ArgVAR_006566
45F9p.Cys178TrpVAR_006567
46F9p.Arg191HisVAR_006568rs137852238
47F9p.Arg191CysVAR_006569rs137852237
48F9p.Arg226TrpVAR_006570rs137852240
49F9p.Arg226GlyVAR_006571
50F9p.Arg226GlnVAR_006572rs137852241
51F9p.Val227AspVAR_006573
52F9p.Val228LeuVAR_006574rs137852243
53F9p.Gln241HisVAR_006575
54F9p.Gly253GluVAR_006576
55F9p.Gly253ArgVAR_006577
56F9p.Ala265ThrVAR_006578
57F9p.Ala279ThrVAR_006579rs137852247
58F9p.Asn283AspVAR_006580
59F9p.Arg294GlyVAR_006582
60F9p.Arg294GlnVAR_006583rs137852249
61F9p.His302ArgVAR_006584
62F9p.Ile316PheVAR_006585
63F9p.Leu321GlnVAR_006586
64F9p.Pro333HisVAR_006587
65F9p.Thr342LysVAR_006588
66F9p.Thr342MetVAR_006589rs137852254
67F9p.Gly351AspVAR_006590
68F9p.Trp356CysVAR_006591
69F9p.Gly357GluVAR_006592rs137852275
70F9p.Lys362GluVAR_006593
71F9p.Gly363TrpVAR_006594
72F9p.Ala366AspVAR_006595
73F9p.Arg379GlyVAR_006596
74F9p.Arg379GlnVAR_006597rs137852259
75F9p.Cys382TyrVAR_006598
76F9p.Lys387GluVAR_006599
77F9p.Ile390PheVAR_006600
78F9p.Met394LysVAR_006601
79F9p.Cys396SerVAR_006602rs137852273
80F9p.Arg404ThrVAR_006603
81F9p.Cys407SerVAR_006604
82F9p.Gly413ArgVAR_006605
83F9p.Val419GluVAR_006606rs137852280
84F9p.Phe424ValVAR_006607
85F9p.Thr426ProVAR_006608
86F9p.Ser430ThrVAR_006609
87F9p.Trp431GlyVAR_006610
88F9p.Trp431ArgVAR_006611
89F9p.Gly432SerVAR_006612
90F9p.Gly432ValVAR_006613
91F9p.Glu433AlaVAR_006614
92F9p.Glu433LysVAR_006615rs767828752
93F9p.Ala436ValVAR_006616rs137852266
94F9p.Arg449GlnVAR_006618rs143018900
95F9p.Arg449TrpVAR_006619rs757996262
96F9p.Tyr450CysVAR_006620
97F9p.Ile454ThrVAR_006621
98F9p.Arg75GlnVAR_017308rs137852228
99F9p.Glu79AspVAR_017309rs137852229
100F9p.Val227PheVAR_017310rs137852242
101F9p.Val228PheVAR_017311rs137852243
102F9p.Cys252SerVAR_017312rs267606792
103F9p.Cys268TrpVAR_017313rs137852246
104F9p.Glu291ValVAR_017314rs137852279
105F9p.Asn306SerVAR_017315rs137852251
106F9p.Gly357ArgVAR_017316rs137852257
107F9p.Ala397ProVAR_017317rs137852281
108F9p.Asp410HisVAR_017318rs137852278
109F9p.Ser411IleVAR_017319rs137852276
110F9p.Ser411GlyVAR_017320rs137852277
111F9p.Pro414ThrVAR_017321rs137852265
112F9p.Gly442ArgVAR_017322rs137852267
113F9p.Ile443ThrVAR_017323rs137852268
114F9p.Trp453ArgVAR_017324rs137852269
115F9p.Cys28TyrVAR_017343
116F9p.Leu52SerVAR_017344
117F9p.Thr84ArgVAR_017345
118F9p.Gly106AspVAR_017346
119F9p.Glu124LysVAR_017347
120F9p.Gly125ArgVAR_017348
121F9p.Cys134TyrVAR_017349
122F9p.Ser169CysVAR_017350
123F9p.Cys170PheVAR_017351
124F9p.Gln241LysVAR_017352
125F9p.Cys252TyrVAR_017353
126F9p.Leu318ArgVAR_017354
127F9p.Pro333ThrVAR_017355
128F9p.Ile344LeuVAR_017356
129F9p.Leu383IleVAR_017357
130F9p.Leu383PheVAR_017358
131F9p.Phe395IleVAR_017359
132F9p.Phe395LeuVAR_017360
133F9p.Cys396PheVAR_017361
134F9p.Cys407ArgVAR_017362
135F9p.Gly412GluVAR_017363
136F9p.Cys435TyrVAR_017364
137F9p.Gly442GluVAR_017365
138F9p.Asn328TyrVAR_073982

Clinvar genetic disease variations for Hemophilia B:

5 (show all 96)
id Gene Variation Type Significance SNP ID Assembly Location
1F9F9, ARG-4TRPSNVPathogenicChr na, -1: -1
2F9F9, ARG-1SERundetermined variantPathogenicChr na, -1: -1
3F9F9, GLU7ASPundetermined variantPathogenicChr na, -1: -1
4F9NM_000133.3(F9): c.169C> T (p.Gln57Ter)SNVPathogenicrs137852223GRCh37Chr X, 138619249: 138619249
5F9NM_000133.3(F9): c.52T> C (p.Cys18Arg)SNVPathogenicrs387906474GRCh37Chr X, 138612975: 138612975
6F9F9, ARG-4GLNSNVPathogenicChr na, -1: -1
7F9NM_000133.3(F9): c.79G> A (p.Glu27Lys)SNVPathogenicrs387906475GRCh37Chr X, 138613002: 138613002
8F9NM_000133.3(F9): c.218A> T (p.Glu73Val)SNVPathogenicrs137852226GRCh37Chr X, 138619298: 138619298
9F9NM_000133.3(F9): c.223C> T (p.Arg75Ter)SNVPathogenicrs137852227GRCh37Chr X, 138619303: 138619303
10F9NM_000133.3(F9): c.224G> A (p.Arg75Gln)SNVPathogenicrs137852228GRCh37Chr X, 138619304: 138619304
11F9NM_000133.3(F9): c.237A> C (p.Glu79Asp)SNVPathogenicrs137852229GRCh37Chr X, 138619317: 138619317
12F9F9, IVS3DS, T-GSNVPathogenicChr na, -1: -1
13F9NM_000133.3(F9): c.278A> G (p.Asp93Gly)SNVPathogenicrs137852230GRCh37Chr X, 138623235: 138623235
14F9NM_000133.3(F9): c.287A> C (p.Gln96Pro)SNVPathogenicrs137852231GRCh37Chr X, 138623244: 138623244
15F9NM_000133.3(F9): c.301C> G (p.Pro101Ala)SNVPathogenicrs137852232GRCh37Chr X, 138623258: 138623258
16F9NM_000133.3(F9): c.316G> A (p.Gly106Ser)SNVPathogenicrs137852233GRCh37Chr X, 138623273: 138623273
17F9NM_000133.3(F9): c.329A> G (p.Asp110Gly)SNVPathogenicrs137852234GRCh37Chr X, 138623286: 138623286
18F9NM_000133.3(F9): c.479G> C (p.Gly160Ala)SNVPathogenicrs137852235GRCh37Chr X, 138630609: 138630609
19F9NM_000133.3(F9): c.496A> T (p.Asn166Tyr)SNVPathogenicrs137852236GRCh37Chr X, 138630626: 138630626
20F9F9, TRP194TERundetermined variantPathogenicChr na, -1: -1
21F9NM_000133.3(F9): c.571C> T (p.Arg191Cys)SNVPathogenicrs137852237GRCh37Chr X, 138633271: 138633271
22F9NM_000133.3(F9): c.572G> A (p.Arg191His)SNVPathogenicrs137852238GRCh37Chr X, 138633272: 138633272
23F9F9, IVS7AS, G-ASNVPathogenicChr na, -1: -1
24F9NM_000133.3(F9): c.880C> T (p.Arg294Ter)SNVPathogenicrs137852248GRCh37Chr X, 138643724: 138643724
25F9NM_000133.3(F9): c.655C> T (p.Gln219Ter)SNVPathogenicrs137852239GRCh37Chr X, 138633355: 138633355
26F9NM_000133.3(F9): c.676C> T (p.Arg226Trp)SNVPathogenicrs137852240GRCh37Chr X, 138633376: 138633376
27F9NM_000133.3(F9): c.541G> T (p.Val181Phe)SNVPathogenicrs387906477GRCh37Chr X, 138633241: 138633241
28F9NM_000133.3(F9): c.682G> T (p.Val228Phe)SNVPathogenicrs137852243GRCh37Chr X, 138633382: 138633382
29F9NM_000133.3(F9): c.709C> T (p.Gln237Ter)SNVPathogenicrs137852244GRCh37Chr X, 138633409: 138633409
30F9NM_000133.3(F9): c.710A> T (p.Gln237Leu)SNVPathogenicrs137852245GRCh37Chr X, 138633410: 138633410
31F9F9, IVS6DS, G-TSNVPathogenicChr na, -1: -1
32F9F9, TRP215TERundetermined variantPathogenicChr na, -1: -1
33F9NM_000133.3(F9): c.804T> G (p.Cys268Trp)SNVPathogenicrs137852246GRCh37Chr X, 138642980: 138642980
34F9NM_000133.3(F9): c.697G> A (p.Ala233Thr)SNVPathogenicrs387906478GRCh37Chr X, 138633397: 138633397
35F9NM_000133.3(F9): c.881G> A (p.Arg294Gln)SNVPathogenicrs137852249GRCh37Chr X, 138643725: 138643725
36F9NM_000133.3(F9): c.892C> T (p.Arg298Ter)SNVPathogenicrs137852250GRCh37Chr X, 138643736: 138643736
37F9NM_000133.3(F9): c.917A> G (p.Asn306Ser)SNVPathogenicrs137852251GRCh37Chr X, 138643761: 138643761
38F9NM_000133.3(F9): c.998C> T (p.Pro333Leu)SNVPathogenicrs137852252GRCh37Chr X, 138643842: 138643842
39F9NM_000133.3(F9): c.1009G> C (p.Ala337Pro)SNVPathogenicrs137852253GRCh37Chr X, 138643853: 138643853
40F9NM_000133.3(F9): c.1025C> T (p.Thr342Met)SNVPathogenicrs137852254GRCh37Chr X, 138643869: 138643869
41F9NM_000133.3(F9): c.1058T> C (p.Val353Ala)SNVPathogenicrs137852255GRCh37Chr X, 138643902: 138643902
42F9NM_000133.3(F9): c.1064G> T (p.Gly355Val)SNVPathogenicrs137852256GRCh37Chr X, 138643908: 138643908
43F9F9, TRP310TERundetermined variantPathogenicChr na, -1: -1
44F9NM_000133.3(F9): c.1069G> A (p.Gly357Arg)SNVPathogenicrs137852257GRCh37Chr X, 138643913: 138643913
45F9NM_000133.3(F9): c.1135C> T (p.Arg379Ter)SNVPathogenicrs137852258GRCh37Chr X, 138643979: 138643979
46F9NM_000133.3(F9): c.1136G> A (p.Arg379Gln)SNVPathogenicrs137852259GRCh37Chr X, 138643980: 138643980
47F9NM_000133.3(F9): c.1144T> C (p.Cys382Arg)SNVPathogenicrs137852260GRCh37Chr X, 138643988: 138643988
48F9NM_000133.3(F9): c.1150C> T (p.Arg384Ter)SNVPathogenicrs137852261GRCh37Chr X, 138643994: 138643994
49F9NM_000133.3(F9): c.1180A> G (p.Met394Val)SNVPathogenicrs137852262GRCh37Chr X, 138644024: 138644024
50F9NM_000133.3(F9): c.1217C> T (p.Ser406Leu)SNVPathogenicrs137852263GRCh37Chr X, 138644061: 138644061
51F9NM_000133.3(F9): c.1088G> T (p.Gly363Val)SNVPathogenicrs387906479GRCh37Chr X, 138643932: 138643932
52F9F9, GLY367ARGundetermined variantPathogenicChr na, -1: -1
53F9NM_000133.3(F9): c.1240C> A (p.Pro414Thr)SNVPathogenicrs137852265GRCh37Chr X, 138644084: 138644084
54F9F9, PHE378LEUundetermined variantPathogenicChr na, -1: -1
55F9NM_000133.3(F9): c.1307C> A (p.Ala436Glu)SNVPathogenicrs137852266GRCh37Chr X, 138644151: 138644151
56F9NM_000133.3(F9): c.1307C> T (p.Ala436Val)SNVPathogenicrs137852266GRCh37Chr X, 138644151: 138644151
57F9NM_000133.3(F9): c.1324G> A (p.Gly442Arg)SNVPathogenicrs137852267GRCh37Chr X, 138644168: 138644168
58F9F9, EX4DELdeletionPathogenicChr na, -1: -1
59F9F9, EX4INSinsertionPathogenicChr na, -1: -1
60F9NM_000133.3(F9): c.1328T> C (p.Ile443Thr)SNVPathogenicrs137852268GRCh37Chr X, 138644172: 138644172
61F9NM_000133.3(F9): c.1357T> C (p.Trp453Arg)SNVPathogenicrs137852269GRCh37Chr X, 138644201: 138644201
62F9NM_000133.3(F9): c.1369A> T (p.Lys457Ter)SNVPathogenicrs137852270GRCh37Chr X, 138644213: 138644213
63F9F9, EX1-8DELdeletionPathogenicChr na, -1: -1
64F9F9, EX1DELdeletionPathogenicChr na, -1: -1
65F9F9, EX1-3DELdeletionPathogenicChr na, -1: -1
66F9F9, EX2-8DELdeletionPathogenicChr na, -1: -1
67F9F9, EX4-5DELdeletionPathogenicChr na, -1: -1
68F9F9, EX5-8DELdeletionPathogenicChr na, -1: -1
69F9F9, EX51INSinsertionPathogenicChr na, -1: -1
70F9F9, EX7DELdeletionPathogenicChr na, -1: -1
71F9F9, 1-BP DEL, ASP85FSdeletionPathogenicChr na, -1: -1
72F9NM_000133.3(F9): c.1120G> T (p.Val374Phe)SNVPathogenicrs137852271GRCh37Chr X, 138643964: 138643964
73F9NM_000133.3(F9): c.484C> T (p.Arg162Ter)SNVPathogenicrs137852272GRCh37Chr X, 138630614: 138630614
74F9NM_000133.3(F9): c.1187G> C (p.Cys396Ser)SNVPathogenicrs137852273GRCh37Chr X, 138644031: 138644031
75F9NM_000133.3(F9): c.328G> A (p.Asp110Asn)SNVPathogenicrs137852274GRCh37Chr X, 138623285: 138623285
76F9NM_000133.3(F9): c.1070G> A (p.Gly357Glu)SNVPathogenicrs137852275GRCh37Chr X, 138643914: 138643914
77F9F9, IVS4, 4442-BP DELdeletionPathogenicChr na, -1: -1
78F9NM_000133.3(F9): c.1232G> T (p.Ser411Ile)SNVPathogenicrs137852276GRCh37Chr X, 138644076: 138644076
79F9NM_000133.3(F9): c.1231A> G (p.Ser411Gly)SNVPathogenicrs137852277GRCh37Chr X, 138644075: 138644075
80F9NM_000133.3(F9): c.1228G> C (p.Asp410His)SNVPathogenicrs137852278GRCh37Chr X, 138644072: 138644072
81F9NM_000133.3(F9): c.872A> T (p.Glu291Val)SNVPathogenicrs137852279GRCh37Chr X, 138643716: 138643716
82F9F9, ALU INSERTION, EX5insertionPathogenicChr na, -1: -1
83F9F9, 17747G-CSNVPathogenicChr na, -1: -1
84F9NM_000133.3(F9): c.31T> A (p.Ser11Thr)SNVPathogenicrs387906480GRCh37Chr X, 138612954: 138612954
85F9NM_000133.3(F9): c.82T> C (p.Cys28Arg)SNVPathogenicrs387906481GRCh37Chr X, 138613005: 138613005
86F9NM_000133.3(F9): c.1256T> A (p.Val419Glu)SNVPathogenicrs137852280GRCh37Chr X, 138644100: 138644100
87F9NM_000133.3(F9): c.1151G> C (p.Arg384Pro)SNVPathogenicrs137852283GRCh37Chr X, 138643995: 138643995
88F9NM_000133.3(F9): c.1189G> C (p.Ala397Pro)SNVPathogenicrs137852281GRCh37Chr X, 138644033: 138644033
89F9F9, 17747G-ASNVPathogenicChr na, -1: -1
90F9NM_000133.3(F9): c.277+2T> CSNVPathogenicrs587776735GRCh37Chr X, 138619547: 138619547
91F9NM_000133.3(F9): c.1031T> C (p.Ile344Thr)SNVPathogenicrs387906482GRCh37Chr X, 138643875: 138643875
92F9NM_000133.3(F9): c.755G> C (p.Cys252Ser)SNVPathogenicrs267606792GRCh37Chr X, 138642931: 138642931
93F9NM_000133.3(F9): c.540_541delAG (p.Arg180Serfs)deletionPathogenicrs587776736GRCh37Chr X, 138633240: 138633241
94F9NM_000133.3(F9): c.1151G> T (p.Arg384Leu)SNVPathogenicrs137852283GRCh37Chr X, 138643995: 138643995
95F9NM_000133.3(F9): c.835G> A (p.Ala279Thr)SNVPathogenicrs137852247GRCh38Chr X, 139560852: 139560852
96F9NM_000133.3(F9): c.278-3A> GSNVPathogenicrs398122990GRCh37Chr X, 138623232: 138623232

Copy number variations for Hemophilia B from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1259590X138440560138473283InsertionF9Hemophilia B

Expression for genes affiliated with Hemophilia B

About this section
Search GEO for disease gene expression data for Hemophilia B.

Pathways for genes affiliated with Hemophilia B

About this section

GO Terms for genes affiliated with Hemophilia B

About this section

Cellular components related to Hemophilia B according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intrinsic component of external side of plasma membraneGO:003123310.4F10, F3
2platelet alpha granule lumenGO:00310939.6EGF, F8
3Golgi lumenGO:00057969.6F10, F2, F7, F9
4endoplasmic reticulum lumenGO:00057889.3F10, F2, F7, F8, F9
5extracellular exosomeGO:00700628.2EGF, F11, F2, F3, F9, SERPINC1
6extracellular spaceGO:00056157.3EGF, F11, F2, F3, F7, F8
7extracellular regionGO:00055767.3EGF, F10, F11, F2, F7, F8
8plasma membraneGO:00058866.5EGF, F10, F11, F2, F3, F7

Biological processes related to Hemophilia B according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1acute-phase responseGO:000695310.4F2, F8
2positive regulation of blood coagulationGO:003019410.2F2, F7
3positive regulation of platelet-derived growth factor receptor signaling pathwayGO:001064110.1F3, F7
4positive regulation of positive chemotaxisGO:005092710.1F3, F7
5regulation of blood coagulationGO:00301939.8F11, F2
6positive regulation of cell migrationGO:00303359.7F10, F3, F7
7positive regulation of protein kinase B signalingGO:00518979.6F10, F3, F7
8blood coagulation, extrinsic pathwayGO:00075989.5F10, F3, F7, F9
9peptidyl-glutamic acid carboxylationGO:00171879.4F10, F2, F7, F9
10ER to Golgi vesicle-mediated transportGO:00068889.1F10, F2, F7, F8, F9
11blood coagulation, intrinsic pathwayGO:00075979.0F10, F11, F2, F8, F9
12signal peptide processingGO:00064658.8F10, F2, F7, F9
13blood coagulationGO:00075967.3F10, F11, F2, F3, F7, F8

Molecular functions related to Hemophilia B according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endopeptidase activityGO:000417510.2F7, F9
2calcium ion bindingGO:00055098.9EGF, F10, F2, F7, F9
3serine-type endopeptidase activityGO:00042527.4F10, F11, F2, F3, F7, F8

Sources for Hemophilia B

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet